CS Mckee LP lessened its stake in shares of Celgene Co. (NASDAQ:CELG) by 1.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 190,950 shares of the biopharmaceutical company’s stock after selling 3,150 shares during the period. Celgene accounts for 2.0% of CS Mckee LP’s portfolio, making the stock its 13th largest holding. CS Mckee LP’s holdings in Celgene were worth $24,799,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Thompson Davis & CO. Inc. grew its stake in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the last quarter. Motco lifted its position in Celgene by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Penserra Capital Management LLC bought a new position in Celgene in the second quarter worth $129,000. Balentine LLC lifted its position in Celgene by 83.5% in the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 481 shares during the period. Finally, Acropolis Investment Management LLC bought a new position in Celgene in the second quarter worth $144,000. Institutional investors own 80.16% of the company’s stock.
Shares of Celgene Co. (NASDAQ CELG) opened at $108.00 on Tuesday. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17. The firm has a market capitalization of $83,526.45, a price-to-earnings ratio of 16.58, a PEG ratio of 0.82 and a beta of 1.78. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the company posted $1.58 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. sell-side analysts predict that Celgene Co. will post 6.67 EPS for the current year.
Several research analysts recently commented on the company. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Celgene in a research report on Sunday. Cantor Fitzgerald set a $112.00 target price on Celgene and gave the stock a “hold” rating in a research report on Monday. Atlantic Securities raised Celgene from a “neutral” rating to an “overweight” rating in a research report on Friday. Cann reaffirmed a “buy” rating and issued a $166.00 target price on shares of Celgene in a research report on Wednesday, November 22nd. Finally, TheStreet cut Celgene from a “b-” rating to a “c+” rating in a research report on Friday, November 17th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and an average target price of $139.57.
In related news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.95% of the stock is owned by company insiders.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.